Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Systematic Review / Meta-analysis

Cancer risk of JAK and TNF inhibitors in RA patients meta-analysis

Comparison of cancer risks associated with JAK inhibitors and TNF inhibitors treatment in patients with rheumatoid arthritis: a systematic review and meta-analysis of real-world cohort studies.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Citation & Authors

Inflamm Res. 2026;75(1):15.

Fu-Yu Yang; Yu-Chang Liu; Min-You Wu; Yao-Cheng Wu; Cheng-Hsien Hung

ABSTRACT · RESEARCH SUMMARY

Research summary

A meta-analysis of 5 real-world cohorts involving 137,640 patients with RA found no significant increase in overall cancer risk with JAK versus TNF inhibitors (HR 1.06; 95% CI 0.81–1.37), but a higher risk of nonmelanoma skin cancer (1.21; 1.03–1.41). GRADE certainty was very low for all findings, which therefore cannot exclude safety concerns in specific high-risk patients.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗